Clinical Trial Update: Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial is evaluating the combination of losartan, pembrolizumab, and stereotactic body radiation therapy for locally recurrent, refractory,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cozaar (losartan)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, Davis | Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING